Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia

摘要: The effect of mirtazapine on steady-state plasma concentrations the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia. In order to treat residual negative symptoms, additional (30 mg per day) administered for six consecutive weeks nine stabilized clozapine therapy (200-650 day), eight (3-8 seven (10-20mg day). There were only minimal statistically insignificant changes mean its metabolite norclozapine, 9-hydroxyrisperidone, during study period. Mirtazapine co-administration either or well tolerated. overall sample, a slight improvement symptomatology, as assessed by Scale Assessment Negative Symptoms, observed at final evaluation (P<0.01) (two each treatment group) classified responders. While double-blind, controlled studies are needed evaluate potential clinical benefits schizophrenia, our findings indicate that has negligible metabolism can be added safely an existing these antipsychotics.